GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRINOX alone as first-line treatment for metastatic pancreatic cancer
Authors
Marc Ychou (ORCID: https://orcid.org/0000-0001-7378-9469)
Catherine Fiess
Eric Assénat (ORCID: https://orcid.org/0000-0002-8958-2793)
Sophie Gourgou (ORCID: https://orcid.org/0000-0002-6328-9839)
GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRINOX alone as first-line treatment for metastatic pancreatic cancer
Marc Ychou, Catherine Fiess, Eric Assénat, Sophie Gourgou et al.
Journal
BMJ Open
Topics
Pancreatic and Hepatic Oncology Research
article
GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRINOX alone as first-line treatment for metastatic pancreatic cancer
Marc Ychou, Catherine Fiess, Eric Assénat, Sophie Gourgou, Fabienne Portalès, Fanny Salasc
article en
Abstract
No abstract available for this paper.
Publication Tag
BMJ OpenVol. 15(8)
Institutions
Université de Montpellier (FR), Centre Hospitalier Universitaire de Montpellier (FR), Institut de Recherche en Cancérologie de Montpellier (FR)